- Genentech Inc.
- Chugai Pharmaceutical Co. Ltd.
- AstraZeneca PLC
- Abbott Laboratories Inc.
- Boston Scientific Corp.
- Guidant Corp.
- Kos Pharmaceuticals Inc.
- Johnson & Johnson
- Pfizer Inc.
- Pfizer Consumer Health Care Group
- Alza Corp.
- Scios Inc.
- Eli Lilly & Co.
- Icos Corp.
- Vernalis PLC
- Elan Corp. PLC
- UCB SA
- Endo International PLC
- Synosia Therapeutics Inc.
- Plexxikon Inc.
- Exelixis Inc.
- Lux Biosciences Inc.
- Magen BioSciences Inc.
- Sirtris Pharmaceuticals Inc.
- Bristol-Myers Squibb Co.
- Amgen Inc.
- Genentech Inc.
- Merck & Co. Inc.
- Nippon Roche acquires majority of Chugai
- Abbott acquires Guidant's vascular business
- Abbott acquires Kos for $3.7bn in cash
- J&J withdraws offer to acquire Guidant
- Boston Scientific wins $27bn bid for Guidant
- J&J to buy Pfizer Consumer Health Care Group for $16.6bn
- J&J agrees to acquire Alza for stock
- J&J buying Scios for $2.69bn cash
- Lilly agrees to buy Icos for $2.1bn
- Elan, UCB Pharma co-promote Frova in the US
- Endo gets N. American rights to Vernalis's Frova
- Synosis Therapeutics completes its $30mm Series A round
- Roche signs on for rights to Plexxikon's PLX4032 cancer agent
- Plexxikon, Wyeth ally in developing diabetes treatments
- BMS, Merck develop muraglitazar for diabetes: terminated
- AZ and BMS enter Type II diabetes deal; BMS later sells diabetes business to AZ
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.